Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1941 2
1945 1
1946 6
1947 5
1948 10
1949 6
1950 9
1951 9
1952 4
1953 6
1954 2
1955 3
1957 2
1958 4
1959 8
1960 3
1961 3
1962 4
1963 3
1964 5
1965 3
1966 3
1967 6
1968 8
1969 7
1970 6
1971 15
1972 9
1973 11
1974 12
1975 9
1976 13
1977 10
1978 14
1979 17
1980 10
1981 8
1982 14
1983 12
1984 24
1985 15
1986 18
1987 13
1988 20
1989 25
1990 21
1991 37
1992 36
1993 51
1994 31
1995 26
1996 24
1997 23
1998 35
1999 28
2000 18
2001 27
2002 20
2003 32
2004 35
2005 50
2006 35
2007 39
2008 39
2009 30
2010 27
2011 39
2012 29
2013 37
2014 33
2015 32
2016 42
2017 47
2018 41
2019 52
2020 46
2021 52
2022 45
2023 45
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

1,513 results

Results by year

Filters applied: . Clear all
Page 1
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S. Lambert J, et al. Among authors: rubin sd. Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076173 Free PMC article. Clinical Trial.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Coleman RL, et al. Among authors: rubin s. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. N Engl J Med. 2019. PMID: 31722153 Free PMC article. Clinical Trial.
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Coleman RL, et al. Among authors: rubin sc. Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21. Lancet Oncol. 2017. PMID: 28438473 Free PMC article. Clinical Trial.
Cancer takes many paths through G1/S.
Knudsen ES, Witkiewicz AK, Rubin SM. Knudsen ES, et al. Among authors: rubin sm. Trends Cell Biol. 2023 Nov 10:S0962-8924(23)00211-8. doi: 10.1016/j.tcb.2023.10.007. Online ahead of print. Trends Cell Biol. 2023. PMID: 37953123 Review.
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Koblish HK, Wu L, Wang LS, Liu PCC, Wynn R, Rios-Doria J, Spitz S, Liu H, Volgina A, Zolotarjova N, Kapilashrami K, Behshad E, Covington M, Yang YO, Li J, Diamond S, Soloviev M, O'Hayer K, Rubin S, Kanellopoulou C, Yang G, Rupar M, DiMatteo D, Lin L, Stevens C, Zhang Y, Thekkat P, Geschwindt R, Marando C, Yeleswaram S, Jackson J, Scherle P, Huber R, Yao W, Hollis G. Koblish HK, et al. Among authors: rubin s. Cancer Discov. 2022 Jun 2;12(6):1482-1499. doi: 10.1158/2159-8290.CD-21-1156. Cancer Discov. 2022. PMID: 35254416 Free PMC article. Clinical Trial.
Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Robert C, et al. Among authors: rubin sd. N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16. N Engl J Med. 2015. PMID: 25399551 Free article. Clinical Trial.
Prolonged grief disorder.
Rubin SS, Malkinson R, Witztum E. Rubin SS, et al. Lancet Psychiatry. 2022 Sep;9(9):696-697. doi: 10.1016/S2215-0366(22)00261-9. Lancet Psychiatry. 2022. PMID: 35964580 No abstract available.
1,513 results